MILAN — Tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist, was more effective than placebo was in the resolution of metabolic dysfunction–associated steatohepatitis and in the improvement of fibrosis, according to the results of the phase 2 SYNERGY-NASH trial.
Overall, approximately 42% of participants had F2 fibrosis and over 57% had F3 fibrosis. The proportion of F3 fibrosis was numerically higher in the placebo and 5-mg tirzepatide groups. A total of 157 participants underwent liver biopsies at week 52, providing results for the current analysis. " Tirzepatide led to significant weight loss in both patients with diabetes and those without diabetes," reported Loomba. "The most common adverse events were gastrointestinal in nature, with 96% of them mild to moderate in severity," said Loomba."Discontinuations occurred in 4.2% of participants, which was similar between patients on tirzepatide and those on placebo.
"These are convincing results in terms of MASH resolution, showing a strong response and dose-dependence," he said.